(PRWEB) May 16, 2012
AdvocureNF2 (http://www.advocurenf2.org) is please to co-sponsor the 3rd State of the Art International NF2 Conference (http://www.nf2international2012.co.uk/index.html). This landmark gathering will be held in Manchester, UK, May 21-22, 2012. Leading doctors and scientists will come together at this major international scientific conference to share their clinical and research findings on Neurofibromatosis type 2 (NF2).
"We are proud to be part of this very important international event. Advocure is committed to helping find a cure for NF2 through our advocacy and education," said Marie Drew, president of NF2 Advocure.
NF2 is a genetic disease affecting 1:25,000 individuals. It is characterized by multiple benign tumors on the cranial and spinal nerves. Tumors affecting both auditory nerves are the hallmark of this disease, often resulting in deafness. Advances in understanding NF2 will not only make lives easier for people with NF2, but promises to have wider implications for understanding tumor formation and growth in a range of cancers.
For the first time, 3rd State of the Art International NF2 Conference is open to patients and members of the NF2 community, who will be able to attend and learn about the latest research and treatments.
AdvocureNF2, Inc., is a nonprofit organization, is a parent/patient advocacy task force for people with NF2. As a co-sponsor of this event, Advocure is contributing funding for captioning of the presentations, which will enable those who are hard-of-hearing or deafened to participate. For more information, visit http://www.advocurenf2.org.